Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
10.18
+0.02 (0.20%)
At close: Oct 2, 2026, 4:00 PM EDT
10.20
+0.02 (0.20%)
After-hours: Oct 2, 2026, 7:51 PM EDT
Candel Therapeutics Employees
Candel Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 17 or 44.74% compared to the previous year.
Employees
55
Change (1Y)
17
Growth (1Y)
44.74%
Revenue / Employee
n/a
Profits / Employee
-$1,609,655
Market Cap
778.96M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 17 | 44.74% |
| Dec 31, 2024 | 38 | -4 | -9.52% |
| Dec 31, 2023 | 42 | -34 | -44.74% |
| Dec 31, 2022 | 76 | 11 | 16.92% |
| Dec 31, 2021 | 65 | 24 | 58.54% |
| Mar 31, 2021 | 50 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 625 |
| Wave Life Sciences | 317 |
| Geron | 258 |
| 4D Molecular Therapeutics | 196 |
| Annexon | 92 |
| Lexicon Pharmaceuticals | 81 |
| Design Therapeutics | 55 |
| Avalo Therapeutics | 33 |
CADL News
- 2 days ago - Candel Therapeutics to Present at the SITC 2026 Annual Meeting - GlobeNewsWire
- 3 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Candel announces final phase 2a trial of aglatimagene, valacyclovir - TheFly
- 3 days ago - Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI - GlobeNewsWire
- 4 days ago - Candel Therapeutics announces data from phase 2 PrTK05 trial - TheFly
- 4 days ago - Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer - GlobeNewsWire
- 4 days ago - Candel Therapeutics announces new data on aglatimagene besadenovec - TheFly
- 4 days ago - Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 - GlobeNewsWire